Tag: trastuzumab

Alteogen, a Korea-based biopharmaceutical company focusing on the development and commercialization of novel anticancer drugs such as antibody-drug conjugates, has received an approval for...

DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...

In an attempt to develop a more effective therapy for human epidermal growth factor receptor 2 (HER2)-positive cancer, a team of researchers led by...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...

Novel, effective, safe and efficient compounds of natural origin t help fight human disease are hard to find. ver the last decades, scientists have...

In 2012, an estimated 2,975,314 women were living with breast cancer, representing about 12% of all new cancer cases and 25% of all cancers...

Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate...